JPRN-C000000397已完成2 期
Phase II study of sequential administration of FEC (Fluorouracil / Epirubicin / Cyclophosphamide) followed by Docetaxel as adjuvant chemotherapy for node-positive breast cancer - Phase II study of FEC followed by Docetaxel as adjuvant chemotherapy for node-positive breast cancer
Kyushu Breast Cancer Study Group0 个研究点目标入组 150 人开始时间: 2006年4月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Bilateral breast cancer 2)A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix 3)Inflammatory breast cancer 4)Male 5)A history of hypersensitivity reaction to any drugs. 6)Uncontrolled medical conditions. 7)Suspected of infection with fever 8)Severe peripheral neuropathy (>Grade 1). 9)Symptomatic varicella. 10)Treatment required pleural or pericardial effusions 11)Severe peripheral edema. 12)Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray 13)Patients who are required concurrent treatment by corticosteroids. 14)Severe psychiatric disorders 15)Pregnant or lactation women, or women with suspected pregnancy 16)Patients judged by the investigator to be unfit to be enrolled into the study
研究者
相似试验
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus Infection - NDEUCTR2009-011786-80-ITZYMOGENETICS, INC.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioEUCTR2009-011786-80-CZZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioChronic Hepatitis C Virus InfectionMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-011786-80-ATZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29Administered in Combination with Ribavirin to Treatment-Naive Subjects with ChronicHepatitis C Virus InfectioChronic Hepatitis C Virus InfectionMedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-011786-80-BEZymoGenetics, Inc.600
进行中（未招募）
不适用
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus InfectioEUCTR2009-011786-80-DEZymoGenetics, Inc.600